Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2023 · 38 (1)
DOI: 10.1080/14756366.2023.2276665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 02.11.2023. Verfasst von Sachin Sharma und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Endometrial Neoplasms, Flavones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Science and Technology Council, SERB.
Abstract (Originalsprache)
Structural tailoring of the flavone framework (position 7) via organopalladium-catalyzed C-C bond formation was attempted in this study. The impact of substituents with varied electronic effects (phenyl ring, position 2 of the benzopyran scaffold) on the antitumor properties was also assessed. Resultantly, the efforts yielded a furyl arm bearing benzopyran possessing a 4-fluoro phenyl ring (position 2) (14) that manifested a magnificent antitumor profile against the Ishikawa cell lines mediated through dual inhibition of PARP and tubulin [(IC50 (PARP1) = 74 nM, IC50 (PARP2) = 109 nM) and tubulin (IC50 = 1.4 µM)]. Further investigations confirmed the ability of 14 to induce apoptosis as well as autophagy and cause cell cycle arrest at the G2/M phase. Overall, the outcome of the study culminated in a tractable dual PARP-tubulin inhibitor endowed with an impressive activity profile against endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Biological Sciences, BITS Pilani KK Birla Goa campus, Goa, India.
- Department of Biological Sciences, National Institute of Pharmaceutical Education and Research, Hyderabad, India.
- Guru Gobind Singh College of Pharmacy, Yamuna Nagar, India.
- Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Förderung
- Ministry of Science and Technology, Taiwan
- National Science and Technology Council
- SERB
- DBT, GOI
Zitieren
APA
Sharma, S., Chandra, K., Naik, A., Sharma, A., Sharma, R., Thakur, A., Grewal, A. S., Dhingra, A. K., Banerjee, A., Liou, J. P., Guru, S. K., & Nepali, K. (2023). Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1). https://doi.org/10.1080/14756366.2023.2276665
Vancouver
Sharma S, Chandra K, Naik A, Sharma A, Sharma R, Thakur A, et al. Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023;38(1). doi:10.1080/14756366.2023.2276665
BibTeX
@article{Sharma2023,
author = {Sharma, Sachin and Chandra, Kavya and Naik, Aliva and Sharma, Anamika and Sharma, Ram and Thakur, Amandeep and Grewal, Ajmer Singh and Dhingra, Ashwani K and Banerjee, Arnab and Liou, Jing Ping and Guru, Santosh Kumar and Nepali, Kunal},
title = {Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2023},
volume = {38},
number = {1},
doi = {10.1080/14756366.2023.2276665}
}
EUVIMED